Related Experiment Video
Updated: Aug 10, 2025

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
Published on: May 26, 2023
Cardiac sympathetic denervation prevents sudden cardiac arrest and improves cardiac function by enhancing
Insights
Cardiac sympathetic denervation (CSD) prevents sudden cardiac arrest (SCA) and heart failure (HF) by improving mitochondrial function. CSD mitigates harmful mitochondrial reactive oxygen species (mROS) and corrects calcium handling, offering new therapeutic avenues for SCA and HF.
Area of Science:
- Cardiology
- Mitochondrial Biology
- Autonomic Nervous System
Background:
- Sudden cardiac arrest (SCA) and heart failure (HF) are leading causes of death with incompletely understood mechanisms.
- Cardiac sympathetic denervation (CSD) shows promise for cardioprotection in HF, but its molecular basis is unclear.
Approach:
- Investigated the role of mitochondrial reactive oxygen species (mROS) in HF and SCA pathogenesis.
- Utilized in vivo and in vitro models of pressure-overload HF to study CSD effects.
- Assessed mROS, Ca2+ handling, and electrophysiological parameters in left ventricular myocytes.
Key Points:
- Pressure-overload HF reduces mitochondrial antioxidant capacity, increasing mROS, impairing beta-adrenergic signaling, and causing SR Ca2+ leak.
- CSD improved cardiac function and reduced SCA risk by upregulating mitochondrial antioxidant and NADPH-producing enzymes.
- CSD mitigated mROS-mediated diastolic Ca2+ overload, repolarization abnormalities, and triggered activity.
Conclusions:
- Sympathetic stress downregulates mROS scavenging enzymes, leading to diastolic Ca2+ overload and contributing to HF and SCA.
- CSD counteracts these effects by enhancing mitochondrial antioxidant capacity and redox balance.
- These findings elucidate CSD's mechanisms and support its evaluation in high-risk patient populations.
Rationale:
Sudden cardiac arrest (SCA) and heart failure (HF) are leading causes of death. The underlying mechanisms are incompletely understood, limiting the design of new therapies. Whereas most autonomic modulation therapies have not shown clear benefit in HF patients, growing evidence indicates cardiac sympathetic denervation (CSD) exerts cardioprotective effects. The underlying molecular and cellular mechanisms remain unexplored.
Objective:
Based on the hypothesis that mitochondrial reactive oxygen species (mROS) drive the pathogenesis of HF and SCA, we investigated whether CSD prevents SCA and HF by improving mitochondrial antioxidant capacity and redox balance, to correct impaired Ca2+ handling and repolarization reserve.
Methods And Results:
We interrogated CSD-specific responses in pressure-overload HF models with spontaneous SCA using in vivo echocardiographic and electrocardiographic studies and in vitro biochemical and functional studies including ratiometric measures of mROS, Ca2+ and sarcomere dynamics in left ventricular myocytes. Pressure-overloaded HF reduced mitochondrial antioxidant capacity and increased mROS, which impaired β-adrenergic signaling and caused SR Ca2+ leak, reducing SR Ca2+ and increasing diastolic Ca2+, impaired myofilament contraction and further increased the sympathetic stress response. CSD improved contractile function and mitigated mROS-mediated diastolic Ca2+ overload, dispersion of repolarization, triggered activity and SCA by upregulating mitochondrial antioxidant and NADPH-producing enzymes.
Conclusions:
Our findings support a fundamental role of sympathetic stress-induced downregulation of mROS scavenging enzymes and RyR-leak mediated diastolic Ca2+ overload in HF and SCA pathogenesis that are mitigated by CSD. This first report on the molecular and cellular mechanisms of CSD supports its evaluation in additional high-risk patient groups.
More Related Videos
06:40Impact of Intracardiac Neurons on Cardiac Electrophysiology and Arrhythmogenesis in an Ex Vivo Langendorff System
Published on: May 22, 2018
08:01Semi-Minimal Invasive Method to Induce Myocardial Infarction in Rats and the Assessment of Cardiac Function by an Isolated Working Heart System
Published on: June 11, 2020
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
Heart Failure Drugs: Inotropic Agents
Heart Failure Drugs: β-Blockers
Pathophysiology of Cardiac Performance